A Randomised Controlled trial on Orthoptek Magnocellular Stimulator versus Occlusion for Amblyopia for the age group of 6 to 19 years, 20 to 40 years and 40 years or more age group

ALL INDIA INSTITUTE OF MEDICAL SCIENCES0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年8月19日

试验速览

暂无简介。

•All patients of refractive and strabismic amblyopia visiting our OPD with clear cornea, strabismus, no lenticular opacities, no retinal or optic nerve pathologies, no mechanical lid cause leading to amblyopia.
•After proper screening and consent patients of refractive and strabismic amblyopia will be randomized on 4- Block basis with, Mild Amblyopia – 30-40%, Moderate Amblyopia 30-40% and Severe Amblyopia – 20%.
•After randomization in the Orthoptek group – The patient will sit at a 1 meter distance from the screen and do exercise of following red and green lights , that flashes at an interval of 150msec, from the Amblyopic eye for 20 mins, both eyes open 5-7 mins and 5 mins from the normal eye. After a break / rest of 1 hour patient will asked to count flashing lights for 200-300 times. Patient will do all these activities under supervision of an Optometrist / Resident. So, in 1hour -1 therapy will be over.
•The Orthoptek therapy will be given on alternate days for the first 2 Weeks – 6 Sittings in first 15 days followed by once biweekly for 4 sittings and once monthly therapy for 2 sittings if needed for maintenance.
•In the conventional Occlusion group – Occlusion will be given for 4-6 hours every 5 days per week for 3 months preferably when they are at home and on leave from school, college and office. The non-improving patients at last follow – up of 6 months will be managed with other modalities of Amblyopia management.

•Patients with any pathological ocular disorders and epilepsy will not be considered

发起方